Furthermore, phase I and II clinical trials demonstrated the efficacy of monoclonal antibodies against IL-6 and its receptor, either as single agents or in combination with other chemotherapeutic agents, radiation, and targeted therapies in various types of cancer [172]. The gene discussed is IL6; the disease is cancer.